Discontinuation due to adverse events was 5.9% on CagriSema vs 3.5% on placebo
Products marked research use only may have uncertain identity, purity, potency, sterility, or storage
Increasing again during that window can make an otherwise workable dose intolerable
1 Additionally, studies show that BPC-157 also counters the increase in inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6, which are crucial for tumor growth, thereby impeding pathways that lead to cancer progression
Use of BPC-157 should be approached with caution due to the lack of human safety data and regulatory approval
Doctors say that we need to learn more about the safety profile of these drugs and better understand the possible dangers for each patient, depending on their medical history